Engineering HCC-selective PET agent

工程HCC-选择性PET剂

• 批准号: 10926330
• 负责人: Freddy Escorcia
• 金额: $ 174.42万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10926330
• 关键词: Ablation; Biological; Cessation of life; Death Rate; Detection; Development; Diagnosis; Disease; Engineering; Excision; Goals; Image; Immunotherapy; Incidence; Intravenous; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of liver; Modality; Molecular; Patient Selection; Patients; Phase; Positron-Emission Tomography; Primary carcinoma of the liver cells; Radiation therapy; Radioembolization; Survival Rate; Transplantation; United States; X-Ray Computed Tomography; cancer type; falls; high risk; imaging agent; improved; intrahepatic; novel; palliative; screening; treatment planning; tumor

Liver cancer is ranked second in cancer-related deaths worldwide. Unlike many other cancer types, the incidence and death rate of liver cancers is rising in the United States, with a 5-year survival of 18% (all stages). Treatment of hepatocellular carcinoma, the most common type of liver cancer, transplant and resection offer curative potential and have 5 year overall survival (OS) rates of 70%, and 40%, respectively. For palliative local treatments, 5 year OS rates fall to 20-35%. Classic imaging of HCC includes Tri-phasic CT scan and MRI, however, these modalities provide little biological information of the tumors, especially after local ablative therapies, compromising our ability to discern active from treated disease. Our goal is to engineer HCC-selective PET agents that will allow us to define the extent of disease to facilitate screening of in patients at high risk of HCC development, aide in treatment planning once HCC has been diagnosed, and help in selecting patients who may benefit from tumor-selective therapies (e.g. immunotherapy, molecular radiotherapy).

肝癌在全球癌症相关死亡中排名第二。与许多其他癌症类型不同，肝癌的发病率和死亡率在美国不断上升，5 年生存率为 18%（所有阶段）。肝细胞癌（最常见的肝癌类型）的治疗、移植和切除具有治愈潜力，5 年总生存 (OS) 率分别为 70% 和 40%。对于姑息性局部治疗，5 年 OS 率降至 20-35%。 HCC 的经典成像包括三相 CT 扫描和 MRI，然而，这些方式提供的肿瘤生物学信息很少，尤其是在局部消融治疗后，损害了我们区分活动性疾病和已治疗疾病的能力。我们的目标是设计 HCC 选择性 PET 试剂，使我们能够确定疾病的程度，以便于筛查 HCC 高风险患者，在诊断出 HCC 后帮助制定治疗计划，并帮助选择可能需要受益于肿瘤选择性治疗（例如免疫治疗、分子放射治疗）。

项目成果

National Cancer Institute support for targeted alpha-emitter therapy.

美国国家癌症研究所支持靶向 α 发射体治疗。

• DOI: 10.1007/s00259-021-05503-z
• 发表时间: 2021
• 期刊: European journal of nuclear medicine and molecular imaging
• 影响因子: 9.1
• 作者: Hong,JulieA;Brechbiel,Martin;Buchsbaum,Jeff;Canaria,ChristieA;Coleman,CNorman;Escorcia,FreddyE;Espey,Michael;Kunos,Charles;Lin,Frank;Narayanan,Deepa;Capala,Jacek
• 通讯作者: Capala,Jacek

Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop.

ASTRO-RSNA 寡转移性疾病研究研讨会论文集。

• DOI: 10.1016/j.ijrobp.2020.05.018
• 发表时间: 2020
• 期刊: International journal of radiation oncology, biology, physics
• 作者: Yu,JamesB;Brock,KristyK;Campbell,AllisonM;Chen,AileenB;Diaz,Roberto;Escorcia,FreddyE;Gupta,Gaorav;Hrinivich,WilliamT;Joseph,Sabrina;Korpics,Mark;Onderdonk,BenjaminE;Pandit-Taskar,Neeta;Wood,BradfordJ;Woodward,WendyA
• 通讯作者: Woodward,WendyA

Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT.

• DOI: 10.1016/j.adro.2023.101212
• 发表时间: 2023-09
• 期刊: Advances in radiation oncology
• 影响因子: 2.3

Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing.

• DOI: 10.1155/2022/3558200
• 发表时间: 2022
• 期刊: STEM CELLS INTERNATIONAL
• 影响因子: 4.3
• 作者: Bian, Jing;Fu, Jianyang;Wang, Xin;Lee, Jihye;Brar, Gagandeep;Escorcia, Freddy E.;Cam, Maggie;Xie, Changqing
• 通讯作者: Xie, Changqing

Reply: Single-Time-Point Tumor Dosimetry Assuming Normal Distribution of Tumor Kinetics.

答复：单时间点肿瘤剂量测定假设肿瘤动力学呈正态分布。

• DOI: 10.2967/jnumed.121.263717
• 发表时间: 2022
• 期刊: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
• 作者: Sgouros,George;Dewaraja,YuniK;Escorcia,Freddy;Graves,StephenA;Hope,ThomasA;Iravani,Amir;Pandit-Taskar,Neeta;Saboury,Babak;James,SaraSt;Zanzonico,PatB
• 通讯作者: Zanzonico,PatB